

Cristobal Belda Iniesta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8738795/publications.pdf>

Version: 2024-02-01

52
papers

3,624
citations

257450

24
h-index

182427

51
g-index

54
all docs

54
docs citations

54
times ranked

6190
citing authors

#	ARTICLE	IF	CITATIONS
1	PI3K/Akt signalling pathway and cancer. <i>Cancer Treatment Reviews</i> , 2004, 30, 193-204.	7.7	1,918
2	Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. <i>Carcinogenesis</i> , 2005, 26, 2095-2104.	2.8	155
3	Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. <i>Lancet Oncology</i> , The, 2007, 8, 889-897.	10.7	140
4	Implications of Oxidative Stress and Cell Membrane Lipid Peroxidation in Human Cancer (Spain). <i>Cancer Causes and Control</i> , 2004, 15, 707-719.	1.8	138
5	KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis. <i>PLoS ONE</i> , 2009, 4, e8199.	2.5	138
6	IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. <i>Oncogene</i> , 2010, 29, 1681-1690.	5.9	121
7	MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. <i>Oncogene</i> , 2006, 25, 3335-3345.	5.9	86
8	DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer. <i>Oncogene</i> , 2011, 30, 668-678.	5.9	77
9	IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFR/Akt pathway in non-small cell lung cancer. <i>Oncogene</i> , 2013, 32, 1274-1283.	5.9	68
10	A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 289-293.	2.4	64
11	EGFR and colon cancer: a clinical view. <i>Clinical and Translational Oncology</i> , 2008, 10, 6-13.	2.4	58
12	A critical role for choline kinase-1 in the aggressiveness of bladder carcinomas. <i>Oncogene</i> , 2009, 28, 2425-2435.	5.9	55
13	Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. <i>International Journal of Colorectal Disease</i> , 2009, 24, 741-748.	2.2	50
14	Analysis of the Concordance in the EGFR Pathway Status Between Primary Tumors and Related Metastases of Colorectal Cancer Patients: Implications for Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2012, 12, 124-131.	1.6	38
15	Role of CHK2 in cancer development. <i>Clinical and Translational Oncology</i> , 2008, 10, 538-542.	2.4	32
16	Molecular biology of malignant gliomas. <i>Clinical and Translational Oncology</i> , 2006, 8, 635-641.	2.4	30
17	A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4145-4154.	7.0	28
18	New screening method for lung cancer by detecting volatile organic compounds in breath. <i>Clinical and Translational Oncology</i> , 2007, 9, 364-368.	2.4	27

#	ARTICLE	IF	CITATIONS
19	Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct: A Hypothesis. <i>Current Stem Cell Research and Therapy</i> , 2009, 4, 314-317.	1.3	27
20	Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 215-221.	2.3	27
21	Metformin: a new option in cancer treatment. <i>Clinical and Translational Oncology</i> , 2011, 13, 363-367.	2.4	27
22	Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers. <i>Clinical and Translational Oncology</i> , 2013, 15, 503-508.	2.4	27
23	Phospholipid Hydroperoxide Glutathione Peroxidase (PHGPx) expression is downregulated in poorly differentiated breast invasive ductal carcinoma. <i>Free Radical Research</i> , 2007, 41, 681-687.	3.3	25
24	Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach. <i>Clinical and Translational Oncology</i> , 2008, 10, 73-77.	2.4	24
25	Targeting Chk2 improves gastric cancer chemotherapy by impairing DNA damage repair. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 347-360.	4.9	24
26	MKP1 repression is required for the chemosensitizing effects of NF- κ B and PI3K inhibitors to cisplatin in non-small cell lung cancer. <i>Cancer Letters</i> , 2009, 286, 206-216.	7.2	22
27	Integral nutritional approach to the care of cancer patients: results from a Delphi panel. <i>Clinical and Translational Oncology</i> , 2018, 20, 1202-1211.	2.4	21
28	New insights in β -tubulin sequence analysis in non-small cell lung cancer. <i>Lung Cancer</i> , 2003, 41, 41-48.	2.0	20
29	Upregulation of Trefoil Factor 3 (TFF3) After Rectal Cancer Chemoradiotherapy Is an Adverse Prognostic Factor and a Potential Therapeutic Target. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 1151-1158.	0.8	19
30	The ALK translocation in advanced non-small cell lung carcinomas: preapproval testing experience at a single cancer centre. <i>Histopathology</i> , 2013, 62, 609-616.	2.9	16
31	Insulin therapy in diabetes and cancer risk: Current understanding and implications for future study. <i>Advances in Therapy</i> , 2011, 28, 1-18.	2.9	13
32	Economic Analysis of the Reduction of Blood Transfusions during Surgical Procedures While Continuous Hemoglobin Monitoring Is Used. <i>Sensors</i> , 2018, 18, 1367.	3.8	13
33	Molecular biology of pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2008, 10, 530-537.	2.4	12
34	ERCC1 and topoisomerase I expression in small cell lung cancer: Prognostic and predictive implications. <i>International Journal of Oncology</i> , 2012, 40, 2104-10.	3.3	12
35	Molecular markers in colorectal cancer: genetic bases for a customised treatment. <i>Clinical and Translational Oncology</i> , 2007, 9, 549-554.	2.4	9
36	Control of oncologic pain in relief of suffering. Our experience. <i>Clinical and Translational Oncology</i> , 2006, 8, 525-532.	2.4	8

#	ARTICLE	IF	CITATIONS
37	Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 403-409.	2.3	8
38	Foot pain: uncommon presentation of lung cancer. <i>BMJ Case Reports</i> , 2012, 2012, bcr1220115360-bcr1220115360.	0.5	7
39	Do β -tubulin pseudogenes really matter?. <i>Lancet Oncology</i> , 2004, 5, 271-272.	10.7	5
40	Checkpoint kinase 1 modulates sensitivity to cisplatin after spindle checkpoint activation in SW620 cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 318-328.	2.8	5
41	Monoclonal antibodies for medical oncology: a few critical perspectives. <i>Clinical and Translational Oncology</i> , 2011, 13, 84-87.	2.4	5
42	Early intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: A subgroup analysis of the NeoPrevent study. <i>Lung Cancer</i> , 2008, 59, 211-218.	2.0	4
43	Translational Proteomics: What Can You Do for True Patients?. <i>Journal of Proteome Research</i> , 2011, 10, 101-104.	3.7	4
44	Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium. <i>Clinical and Translational Oncology</i> , 2005, 7, 239-243.	2.4	3
45	Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race. <i>Clinical and Translational Oncology</i> , 2011, 13, 774-779.	2.4	3
46	Atrioventricular nodal blocking secondary to melanoma infiltration. <i>Melanoma Research</i> , 2003, 13, 433-434.	1.2	2
47	Retroperitoneal Castleman's disease with colon cancer. A rare association. <i>Clinical and Translational Oncology</i> , 2008, 10, 238-240.	2.4	2
48	Study of the prevalence of tumour-related asthenia in Spanish cancer patients. <i>Clinical and Translational Oncology</i> , 2008, 10, 351-358.	2.4	2
49	EPO-R Expression Patterns in Resected Gastric Adenocarcinoma Followed by Adjuvant Chemoradiation Treatment. <i>Pathology and Oncology Research</i> , 2009, 15, 1-10.	1.9	2
50	The combination of FOLFOX4 and bevacizumab may enable salvage surgery of unresectable liver metastases in colon cancer. <i>Anti-Cancer Drugs</i> , 2009, 20, S4-S6.	1.4	2
51	Doomed Trials for Promising Adenoviruses. <i>Journal of Clinical Oncology</i> , 2004, 22, 1162-1163.	1.6	1
52	Cost-effectiveness, cancer burden and financial crisis: a perfect storm. <i>Clinical and Translational Oncology</i> , 2012, 14, 713-714.	2.4	0